ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
53 announcements with these filters
MedPlus reports drug license suspensions for three stores. The incident causes a minimal potential revenue loss of ₹0.02 Crore.
MedPlus subsidiary Optival Health's Karnataka store faced a one-day drug license suspension. This resulted in a potential revenue loss of ₹0.0046 Crore.
Medplus subsidiary stores in Andhra Pradesh faced drug license suspensions. This results in a total potential revenue loss of ₹0.03 Crore.
MedPlus subsidiary received a two-day drug license suspension in Karnataka. The potential revenue loss is Rs 1.48 lacs, with limited financial impact.
MedPlus subsidiary Optival Health Solutions faced a 15-day drug license suspension at its Ongole store. The disruption causes an estimated ₹0.02 Crore revenue loss.
MedPlus subsidiary Optival Health Solutions received drug license suspensions for two Telangana stores. The temporary closures result in a combined potential revenue loss of ₹0.01 Crore.
MedPlus subsidiary Optival Health Solutions received drug license suspension orders for two Karnataka stores. The temporary closures will result in a combined ₹0.03 Crore revenue loss.
MedPlus Health Services subsidiary received two drug license suspension orders for stores in Telangana and Karnataka. The suspensions cause a ₹0.05 Crore total potential revenue loss.
MedPlus subsidiary Optival Health Solutions received a three-day drug license suspension for a Telangana store. The event carries a potential ₹0.02 Crore revenue impact.
MedPlus subsidiary Optival Health Solutions received a two-day drug license suspension for its Karnataka store. The temporary closure results in a ₹0.01 Crore revenue loss.
MedPlus subsidiary received drug license suspension orders for two Karnataka stores, totaling ₹0.03 Crore in potential revenue loss. Operations will halt temporarily at affected locations.
MedPlus subsidiary Optival Health Solutions received a one-day drug license suspension for its Delhi store. The impact is minimal with ₹0.00 Crore estimated revenue loss.
MedPlus subsidiary Optival Health received one-day drug license suspensions for two stores in Telangana and Karnataka. The temporary closures carry a total potential revenue loss of ₹0.24 lacs.
MedPlus subsidiary Optival Health Solutions received a five-day drug license suspension for its Nashik store from Maharashtra regulatory authorities. The suspension, due to alleged Rule 65 violations, results in a potential revenue loss of ₹0.75 lacs (₹0.01 Crore).
MedPlus subsidiary Optival Health Solutions received a 65-day drug license suspension order for its Durg, Chhattisgarh store. The suspension, issued by the Assistant Drugs Controller, results in a potential revenue loss of ₹0.16 Crore.
MedPlus Health Services' subsidiary, Optival Health Solutions, received a three-day drug license suspension for a store in Ganeshpeth, Hubli. The suspension, issued by Karnataka's Drugs Control Administration, involves an estimated potential revenue loss of ₹0.01 Crore. The company is complying with the order issued under the Drugs and Cosmetics Act.
MedPlus subsidiary Optival Health Solutions received a five-day drug license suspension for its Jayanagar, Karnataka store. The suspension, effective from April 21, 2026, results in a potential revenue loss of ₹0.05 Crore.
MedPlus Health Services Limited's subsidiary received suspension orders for drug licenses at two stores in Andhra Pradesh and Telangana. The suspensions, lasting seven and two days respectively, carry a combined potential revenue loss of approximately ₹0.01 Crore. Operations at these specific locations will be temporarily disrupted due to regulatory non-compliance under the Drugs and Cosmetics Rules.
MedPlus Health subsidiary Optival Health Solutions received suspension orders for drug licenses at two Karnataka stores. The suspensions, lasting four and five days respectively, involve a combined potential revenue loss of ₹0.05 Crore. The action was taken by the Bangalore Drugs Control Administration under the Drugs and Cosmetics Act.
MedPlus Health Services' subsidiary, Optival Health Solutions, received drug license suspension orders for two stores in Andhra Pradesh and Odisha. The suspensions, lasting seven and two days respectively, carry a combined potential revenue loss of ₹0.07 Crore. The actions were taken due to alleged violations of the Drugs and Cosmetics Rules, 1945.
MedPlus Health Services' subsidiary, Optival Health Solutions, received a five-day drug license suspension for its Odisha store. The suspension, effective from April 10, 2026, involves a potential revenue loss of ₹0.04 Crore.
MedPlus subsidiary Optival Health Solutions received a two-day drug license suspension order for a store in Jadcherla, Telangana. The suspension, effective from April 8, 2026, carries a negligible estimated revenue loss of ₹0.28 lacs (approximately ₹0.00 Crore) and follows alleged violations of the Drugs and Cosmetics Act, 1940.
MedPlus Health Services' subsidiary, Optical Health Solutions, received a two-day drug license suspension for its Jangaon, Telangana store. Issued by the Drugs Control Administration for Rule 65 violations, the suspension carries a negligible estimated revenue impact of ₹0.00 Crore (Rs 0.16 lacs).